- Home
- TEN vs QURE Comparison
TEN vs QURE Comparison
Compare TEN & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEN
- QURE
- Stock Information
- Founded
- TEN 1993
- QURE 1998
- Country
- TEN Greece
- QURE Netherlands
- Employees
- TEN N/A
- QURE N/A
- Industry
- TEN
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- TEN
- QURE Health Care
- Exchange
- TEN NYSE
- QURE Nasdaq
- Market Cap
- TEN 620.9M
- QURE 725.4M
- IPO Year
- TEN N/A
- QURE 2007
- Fundamental
- Price
- TEN $19.08
- QURE $14.84
- Analyst Decision
- TEN Buy
- QURE Strong Buy
- Analyst Count
- TEN 2
- QURE 10
- Target Price
- TEN $30.50
- QURE $37.20
- AVG Volume (30 Days)
- TEN 374.0K
- QURE 1.1M
- Earning Date
- TEN 09-10-2025
- QURE 07-31-2025
- Dividend Yield
- TEN 7.83%
- QURE N/A
- EPS Growth
- TEN N/A
- QURE N/A
- EPS
- TEN 4.46
- QURE N/A
- Revenue
- TEN $799,523,000.00
- QURE $20,201,000.00
- Revenue This Year
- TEN N/A
- QURE N/A
- Revenue Next Year
- TEN $8.89
- QURE $278.91
- P/E Ratio
- TEN $4.36
- QURE N/A
- Revenue Growth
- TEN N/A
- QURE 6.30
- 52 Week Low
- TEN $13.40
- QURE $4.45
- 52 Week High
- TEN $27.49
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- TEN 48.16
- QURE 50.88
- Support Level
- TEN $18.92
- QURE $13.55
- Resistance Level
- TEN $19.59
- QURE $15.84
- Average True Range (ATR)
- TEN 0.57
- QURE 0.69
- MACD
- TEN -0.20
- QURE 0.04
- Stochastic Oscillator
- TEN 17.59
- QURE 48.36
About TEN TSAKOS ENERGY NAVIGATION
Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.